Egetis Therapeutics AB (PDPHF) Ratios
Egetis Therapeutics AB Ratios
PDPHF's free cash flow for Q2 2026 was $-95.00M. For the 2026 fiscal year, PDPHF's free cash flow was decreased by $-1.00M and operating cash flow was $-94.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.05 | 1.86 | 3.33 | 2.98 | 3.90 |
| Quick Ratio | 1.04 | 1.86 | 3.32 | 2.97 | 3.89 |
| Cash Ratio | 0.90 | 1.72 | 2.92 | 2.59 | 3.68 |
| Solvency Ratio | -1.13 | -1.15 | -1.51 | -3.40 | -2.42 |
| Operating Cash Flow Ratio | -1.11 | -1.12 | -2.68 | -3.51 | -3.32 |
| Short-Term Operating Cash Flow Coverage | -8.48 | -7.57 | -53.54 | 0.00 | 0.00 |
| Net Current Asset Value | $ -46.80M | $ 80.70M | $ 131.30M | $ 92.50M | $ 110.67M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.15 | 0.15 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.27 | 0.24 | 0.21 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.21 | 0.19 | 0.17 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.15 | 0.16 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.89 | 1.61 | 1.39 | 1.11 | 1.08 |
| Debt Service Coverage Ratio | -6.34 | -5.67 | -34.32 | -1867.00 | -510.44 |
| Interest Coverage Ratio | -15.28 | -12.72 | -79.22 | -1981.00 | -528.40 |
| Debt to Market Cap | 0.04 | 0.05 | 0.08 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.31 | 0.47 | 0.46 | 0.01 | 0.02 |
| Net Debt to EBITDA | 0.36 | 0.74 | 0.60 | 0.65 | 1.37 |
| Profitability Margins | |||||
| Gross Profit Margin | 19.87% | 74.84% | -255.03% | -533.78% | -152.40% |
| EBIT Margin | -555.93% | -688.29% | -560.24% | -860.89% | -272.73% |
| EBITDA Margin | -550.00% | -688.29% | -553.99% | -848.89% | -266.45% |
| Operating Profit Margin | -555.93% | -714.53% | -563.89% | -880.44% | -276.34% |
| Pretax Profit Margin | -548.24% | -744.47% | -567.36% | -861.33% | -273.36% |
| Net Profit Margin | -548.88% | -745.34% | -567.53% | -842.22% | -273.85% |
| Continuous Operations Profit Margin | -548.88% | -745.12% | -567.53% | -861.33% | -273.25% |
| Net Income Per EBT | 100.12% | 100.12% | 100.03% | 97.78% | 100.18% |
| EBT Per EBIT | 98.62% | 104.19% | 100.62% | 97.83% | 98.92% |
| Return on Assets (ROA) | -53.59% | -43.37% | -43.00% | -33.77% | -18.40% |
| Return on Equity (ROE) | -101.12% | -69.72% | -59.92% | -37.44% | -19.87% |
| Return on Capital Employed (ROCE) | -87.12% | -56.01% | -49.49% | -38.71% | -19.94% |
| Return on Invested Capital (ROIC) | -79.16% | -53.04% | -48.94% | -37.74% | -19.88% |
| Return on Tangible Assets | -128.86% | -89.41% | -93.11% | -125.66% | -66.30% |
| Earnings Yield | -17.42% | -16.01% | -22.82% | -13.74% | -8.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.24 | 1.95 | 2.04 | 2.21 | 5.63 |
| Payables Turnover | 2.29 | 0.45 | 7.13 | 7.13 | 20.98 |
| Inventory Turnover | 21.74 | 11.60 | 292.14 | 237.67 | 139.09 |
| Fixed Asset Turnover | 6.43 | 17.73 | 13.09 | 8.33 | 8.95 |
| Asset Turnover | 0.10 | 0.06 | 0.08 | 0.04 | 0.07 |
| Working Capital Turnover Ratio | 0.66 | 0.22 | 0.34 | 0.21 | 0.22 |
| Cash Conversion Cycle | 20.85 | -590.34 | 128.72 | 115.81 | 50.08 |
| Days of Sales Outstanding | 163.20 | 186.85 | 178.70 | 165.47 | 64.85 |
| Days of Inventory Outstanding | 16.79 | 31.47 | 1.25 | 1.54 | 2.62 |
| Days of Payables Outstanding | 159.14 | 808.66 | 51.22 | 51.19 | 17.39 |
| Operating Cycle | 179.99 | 218.32 | 179.95 | 167.00 | 67.48 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -0.74 | -1.08 | -0.89 | -0.72 |
| Free Cash Flow Per Share | -0.73 | -0.74 | -1.08 | -0.89 | -0.72 |
| Dividend Paid and CapEx Coverage Ratio | -178.07 | 0.00 | 0.00 | 0.00 | -756.45 |
| Capital Expenditure Coverage Ratio | -178.07 | 0.00 | 0.00 | 0.00 | -756.45 |
| Operating Cash Flow Coverage Ratio | -2.95 | -1.94 | -2.46 | -64.26 | -30.98 |
| Operating Cash Flow to Sales Ratio | -4.28 | -4.94 | -4.83 | -7.71 | -3.40 |
| Free Cash Flow Yield | -13.66% | -10.62% | -19.43% | -12.58% | -10.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.74 | -6.25 | -4.38 | -7.28 | -11.53 |
| Price-to-Sales (P/S) Ratio | 31.51 | 46.55 | 24.87 | 61.29 | 31.57 |
| Price-to-Book (P/B) Ratio | 5.81 | 4.35 | 2.63 | 2.72 | 2.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.32 | -9.42 | -5.15 | -7.95 | -9.27 |
| Price-to-Operating Cash Flow Ratio | -7.36 | -9.42 | -5.15 | -7.95 | -9.28 |
| Price-to-Earnings Growth (PEG) Ratio | 0.34 | 0.53 | -0.15 | -0.11 | 0.15 |
| Enterprise Value Multiple | -5.36 | -6.03 | -3.89 | -6.57 | -10.48 |
| Enterprise Value | 1.84B | 1.91B | 1.24B | 1.25B | 1.07B |
| EV to EBITDA | -5.36 | -6.03 | -3.89 | -6.57 | -10.48 |
| EV to Sales | 29.50 | 41.48 | 21.57 | 55.74 | 27.91 |
| EV to Free Cash Flow | -6.85 | -8.39 | -4.46 | -7.23 | -8.19 |
| EV to Operating Cash Flow | -6.89 | -8.39 | -4.46 | -7.23 | -8.20 |
| Tangible Book Value Per Share | -0.09 | 0.28 | 0.53 | 0.49 | 0.64 |
| Shareholders’ Equity Per Share | 0.92 | 1.61 | 2.13 | 2.61 | 2.93 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | 0.02 | -0.00 |
| Revenue Per Share | 0.17 | 0.15 | 0.22 | 0.12 | 0.21 |
| Net Income Per Share | -0.93 | -1.12 | -1.27 | -0.98 | -0.58 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.98 | 1.00 |
| Interest Burden | 0.99 | 1.08 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 2.54 | 3.17 | 0.00 | 6.06 | 2.32 |
| SG&A to Revenue | 3.22 | 4.67 | 1.50 | 0.00 | 0.38 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.14 | 0.39 | 0.03 |
| Income Quality | 0.78 | 0.66 | 0.85 | 0.90 | 1.24 |
Currency in SEK